<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Omega‐3 fatty acid supplementation for cystic fibrosis - Watson, H - 2020 | Cochrane Library</title> <meta content="Omega‐3 fatty acid supplementation for cystic fibrosis - Watson, H - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002201.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Omega‐3 fatty acid supplementation for cystic fibrosis - Watson, H - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002201.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002201.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Omega‐3 fatty acid supplementation for cystic fibrosis" name="citation_title"/> <meta content="Helen Watson" name="citation_author"/> <meta content="Cambridge University Hospitals NHS Foundation Trust" name="citation_author_institution"/> <meta content="Helen.watson@addenbrookes.nhs.uk" name="citation_author_email"/> <meta content="Caroline Stackhouse" name="citation_author"/> <meta content="Royal Papworth Hospital NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD002201.pub6" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/04/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002201.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002201.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002201.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Dietary Supplements; Bias; Cystic Fibrosis [blood, *diet therapy]; Disease Progression; Fatty Acids, Omega‐3 [*administration &amp; dosage, adverse effects]; Fatty Acids, Omega‐6 [administration &amp; dosage]; Forced Expiratory Volume; Olive Oil [administration &amp; dosage]; Randomized Controlled Trials as Topic; Vital Capacity" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002201.pub6&amp;doi=10.1002/14651858.CD002201.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="XHP2gG4h";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002201\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002201\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ja","fa","zh_HANT","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002201.pub6",title:"Omega\\u20103 fatty acid supplementation for cystic fibrosis",firstPublishedDate:"Apr 10, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002201.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002201.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002201.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002201.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002201.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002201.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002201.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002201.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002201.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002201.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3664 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002201.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-sec-0080"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/appendices#CD002201-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/table_n/CD002201StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/table_n/CD002201StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Omega‐3 fatty acid supplementation for cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information#CD002201-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Helen Watson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information#CD002201-cr-0003">Caroline Stackhouse</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information/en#CD002201-sec-0097">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 April 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002201.pub6">https://doi.org/10.1002/14651858.CD002201.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002201-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002201-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002201-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002201-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002201-abs-0008">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002201-abs-0001" lang="en"> <section id="CD002201-sec-0001"> <h3 class="title" id="CD002201-sec-0001">Background</h3> <p>Studies suggest that a diet rich in omega‐3 essential fatty acids may have beneficial anti‐inflammatory effects for chronic conditions such as cystic fibrosis. This is an updated version of a previously published review. </p> </section> <section id="CD002201-sec-0002"> <h3 class="title" id="CD002201-sec-0002">Objectives</h3> <p>To determine whether there is evidence that omega‐3 polyunsaturated fatty acid supplementation reduces morbidity and mortality and to identify any adverse events associated with supplementation. </p> </section> <section id="CD002201-sec-0003"> <h3 class="title" id="CD002201-sec-0003">Search methods</h3> <p>We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of last search: 01 April 2020. </p> <p>We also searched online study registries and contacted authors. Date of last search: 12 February 2020. </p> </section> <section id="CD002201-sec-0004"> <h3 class="title" id="CD002201-sec-0004">Selection criteria</h3> <p>Randomised controlled trials in people with cystic fibrosis comparing omega‐3 fatty acid supplements with placebo. </p> </section> <section id="CD002201-sec-0005"> <h3 class="title" id="CD002201-sec-0005">Data collection and analysis</h3> <p>Two authors independently selected studies for inclusion, extracted data and assessed the risk of bias of the studies. The quality of the evidence was assessed using GRADE. </p> </section> <section id="CD002201-sec-0006"> <h3 class="title" id="CD002201-sec-0006">Main results</h3> <p>The searches identified 23 studies; five studies with 106 participants (children and adults) were included; duration of studies and interventions differed. Two studies compared omega‐3 fatty acids to olive oil for six weeks; one study compared omega‐3 fatty acids and omega‐6 fatty acids to control capsules (customised fatty acid blends) for three months; one study compared a liquid dietary supplement containing omega‐3 fatty acids to one without for six months; and one study compared omega‐3 fatty acids to a placebo for 12 months. Three studies had a low risk of bias for randomisation, but the risk was unclear in the remaining two studies; all studies had an unclear risk of bias for allocation concealment. Three of the studies adequately blinded participants; the risk of bias for selective reporting was high in one study and unclear for four studies. </p> <p>Two studies reported the number of respiratory exacerbations. At three months, one study (43 participants) reported no change in antibiotic usage. At 12 months the second study (15 participants) reported a reduction in the number of pulmonary exacerbations and cumulative antibiotic days in the supplement group compared to the previous year (no data for the control group); very low‐quality evidence means we are unsure whether supplementation has any effect on this outcome. </p> <p>With regards to adverse events, one six‐week study (12 participants) reported no difference in diarrhoea between omega‐3 or placebo capsules; the very low‐quality evidence means we are unsure if supplementation has any effect on this outcome. Additionally, one study reported an increase in steatorrhoea requiring participants to increase their daily dose of pancreatic enzymes, but three studies had already increased pancreatic enzyme dose at study begin so as to reduce the incidence of steatorrhoea. One study (43 participants) reported stomach pains at three months (treatment or control group not specified). One six‐week study (19 participants) reported three asthma exacerbations leading to exclusion of participants since corticosteroid treatment could affect affect essential fatty acid metabolism. </p> <p>Four studies reported lung function. One six‐week study (19 participants) reported an increase in forced expiratory volume in one second (FEV<sub>1</sub>) (L) and forced vital capacity (FVC) (L), but the very low‐quality evidence means we are unsure if supplementation has any effect on lung function. The remaining studies did not report any difference in lung function at three months (unit of measurement not specified) or at six months and one year (FEV<sub>1</sub> % predicted and FVC % predicted). </p> <p>No deaths were reported in any of the five studies. Four studies reported clinical variables. One study reported an increase in Schwachman score and weight alongside a reduction in sputum volume with supplementation compared to placebo at three months (data not analysable). However, three studies reported no differences in either weight at six weeks, in body mass index (BMI) standard deviation (SD) score at six months (very low‐quality evidence) or BMI Z score at 12 months. </p> <p>Three studies reported biochemical markers of fatty acid status. One study showed an increase from baseline in both EPA and DHA content of serum phospholipids in the omega‐3 group compared to placebo at three months and also a significant decrease in n‐6/n‐3 ratio in the supplement group compared to placebo; since the quality of the evidence is very low we are not certain that these changes are due to supplementation. One six‐month cross‐over study showed a higher EPA content of the neutrophil membrane in the supplement group compared to the placebo group, but, no difference in DHA membrane concentration. Furthermore, the leukotriene B<sub>4</sub> to leukotriene B<sub>5</sub> ratio was lower at six months in the omega‐3 group compared to placebo. A one‐year study reported a greater increase in the essential fatty acid profile and a decrease in AA levels in the treatment arm compared to placebo. </p> </section> <section id="CD002201-sec-0007"> <h3 class="title" id="CD002201-sec-0007">Authors' conclusions</h3> <p>This review found that regular omega‐3 supplements may provide some limited benefits for people with cystic fibrosis with relatively few adverse effects: however, the quality of the evidence across all outcomes was very low. The current evidence is insufficient to draw firm conclusions or recommend routine use of these supplements in people with cystic fibrosis. A large, long‐term, multicentre, randomised controlled study is needed to determine any significant therapeutic effect and to assess the influence of disease severity, dosage and duration of treatment. Future researchers should note the need for additional pancreatic enzymes when providing omega‐3 supplementation or olive oil placebo capsules. More research is required to determine the exact dose of pancreatic enzyme required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002201-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002201-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002201-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002201-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002201-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD002201-abs-0005">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002201-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002201-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD002201-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002201-abs-0003" lang="en"> <h3>The use of omega‐3 supplements in people with cystic fibrosis</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of giving omega‐3 supplements to people with cystic fibrosis. </p> <p><b>Background</b> </p> <p>In people with cystic fibrosis recurring cycles of infection and inflammation are thought to worsen lung function. Studies suggest that omega‐3 fatty acids, such as those derived from fish oils, may work to counter the inflammation and may be of benefit in chronic inflammatory diseases including cystic fibrosis. This is an updated version of the review. </p> <p><b>Search date</b> </p> <p>The evidence is current to: 01 April 2020.</p> <p><b>Study characteristics</b> </p> <p>This review includes five small studies which compare omega‐3 supplements to a different supplement without omega‐3. In total there were 106 participants, including both children and adults. The studies lasted between six weeks and 12 months. </p> <p><b>Key results</b> </p> <p>Due to the very low‐quality evidence, we are uncertain whether the following effects are due to supplementation or not. One 12‐month study reported a reduction in pulmonary exacerbations and antibiotic use when taking omega‐3 supplementation compared to placebo and one three‐month study reported no change in antibiotic use during the study period. Few side effects were reported in any of the studies. One six‐week study reported that lung function and clinical status improved when taking omega‐3 supplements. Sputum levels were also noted to be reduced in this six‐week study. Three studies reported no difference in lung function when taking omega‐3 supplementation compared to placebo. Two longer studies found that people taking omega‐3 supplements showed definite increases in levels of essential fatty acids in their white blood cell membranes and also in levels of phospholipids (molecules that provide structure and protection to cells) measured in blood samples. </p> <p>We are uncertain whether regular omega‐3 supplements benefit people with cystic fibrosis and whether they cause side effects, or not. We are not able to draw firm conclusions or recommend the routine use of these supplements in people with cystic fibrosis. Larger and longer studies are needed to assess the clinical benefit of omega‐3 supplementation and to determine the appropriate dosage. </p> <p><b>Quality of the evidence</b> </p> <p>We judged the quality of the evidence to be very low due to very low participant numbers, low event rates, limited reporting and poor study design. There was no consistency with regards to the time points when results were reported or the measurements used for the same outcome in different studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002201-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002201-sec-0086"></div> <h3 class="title" id="CD002201-sec-0087">Implications for practice</h3> <section id="CD002201-sec-0087"> <p>We conclude that the limited evidence from these five small studies is not adequate to support any change in clinical practice. The reported benefits, from the use of omega‐3 fatty acid supplements, are from small studies in which the quality of the evidence is very low and hence cannot be used to make recommendations for practice (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>, <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> <p>There is very little evidence to recommend that people with cystic fibrosis (CF) supplement or modify their intake of omega‐3 fatty acid supplements in order to improve control of their condition. Equally, there is an absence of evidence that they are at risk if they do so. Although the data are sparse, it would seem prudent for people with CF taking omega‐3 fatty acid supplements to take no more than the recommended dose for the general non‐CF population. Although the appropriate dose increase has not been determined, an increase in pancreatic enzymes should be considered when taking these supplements. </p> </section> <h3 class="title" id="CD002201-sec-0088">Implications for research</h3> <section id="CD002201-sec-0088"> <p>Further large, long‐term, multicentre, randomised, controlled studies are needed in order to determine if there is a significant therapeutic effect and to assess the influence of disease severity, dosage and duration of treatment. Future researchers should note the prevalence for an increased dose of pancreatic enzymes when administering omega‐3 supplementation or oil based placebo to people with CF. The exact dose of pancreatic enzyme required is yet to be determined. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002201-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002201-sec-0015"></div> <div class="table" id="CD002201-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: omega‐3 fatty acid supplementation compared with placebo for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Omega‐3 fatty acid supplementation compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: oral omega‐3 supplementation (EPA or DHA, or both) </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 supplementation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations</b> (median number of exacerbations during the study) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The number of exacerbations in the placebo group was greater than in the omega‐3 group (3.5 versus 1.7 (range 1 ‐ 3)). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors only report the number of exacerbations in the supplemented group compared to the 12 months prior to the trial. Extra data was provided by the study authors to allow a between group comparison. </p> <p>This outcome was not included in the study protocol.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b>: diarrhoea </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported drop out due to diarrhoea. 2 out of 7 participants in the fish oil group dropped out and 2 out of 5 participants in the placebo group, OR 0.6 (0.05 to 6.79). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.6 (0.05 to 6.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other adverse events included stomach pains (5/35 participants) but the intervention arm wasn't specified (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted was 64% in the control group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted in the intervention group was 2% higher (19.1% lower to 23.11% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.00 (19.11 to 23.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further study (n = 16) reported a significant increase from baseline in the EPA group compared to the control group measured in L compared to the placebo group (P = 0.06) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> <p>Two studies reported no difference in FEV<sub>1</sub> % predicted or lung function (measurement not stated) between groups (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FVC % predicted in the control group was 81%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FVC % predicted in the intervention group was 1% lower (16.65 % lower to 14.65 % higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.00 (‐16.65 to 14.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported a significant rise in FVC (L) in the EPA group (P = 0.01) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> <p>2 studies reported no difference in FVC between groups, but no data were available for analysis (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Growth and nutrition</b>: BMI SD score </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference was seen between the PUFA group and the placebo group after 6 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.00 (95 % CI ‐0.64 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further study reported on BMI but reported only that BMI z scores remained stable throughout the study (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biochemical markers of essential fatty acid status</b>: EPA and DHA % content of neutrophil membrane </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported a higher EPA content of the neutrophil membrane in the omega‐3 PUFA‐supplemented group compared to the placebo group, MD 0.90 (95% CI 0.46 to 1.34). </p> <p>In the same study, no difference was observed in DHA membrane concentration between groups, MD 0.10 (95% CI ‐0.45 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 months, Keen reported a significant increase from baseline in both EPA and DHA content of serum phospholipids in the omega‐3 supplemented group compared to placebo, MD 0.70 (95% CI 0.42 to 0.98) and MD 1.10 (95% CI 0.39 to 1.81), respectively (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>DHA</b> : docosahexaenoic acid; <b>EPA</b> : eicosapentaenoic acid; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>OR</b> : odds ratio; <b>PUFA</b> : polyunsaturated fatty acid; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to risk of bias within the included study for this outcome. There was uncertainty around allocation concealment and blinding and a high risk of bias due to selective reporting. </p> <p><sup>b</sup>Downgraded once due to imprecision from very low participant numbers and low event rates. </p> <p><sup>c</sup>Downgraded once due to risk of bias within the included study. It was unclear whether allocation was concealed and whether the outcomes were predefined as there was no protocol available. </p> <p><sup>d</sup>Downgraded twice due to very low participant numbers (n = 12) and low event rates. </p> <p><sup>e</sup>Downgraded twice due to risk of bias within the trial. The risk of bias was unclear across several domains including; randomisation, allocation concealment, incomplete outcome assessment and selective reporting. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002201-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002201-sec-0016"></div> <section id="CD002201-sec-0017"> <h3 class="title" id="CD002201-sec-0017">Description of the condition</h3> <p>Cystic fibrosis (CF) is the most common life‐threatening genetically inherited disease in populations of Northern European descent, affecting approximately one in 2500 births (<a href="./references#CD002201-bbs2-0025" title="LittlewoodJ , GreenM , StannardW . Finding Out. CF Trust Factsheet2006. ">CF Trust 2006</a>; <a href="./references#CD002201-bbs2-0047" title="UK CFTrust . UK Cystic Fibrosis Registry Annual Data Report 2018. www.cysticfibrosis.org.uk2019. ">UK CF Registry 2018</a>). Pulmonary inflammation is believed responsible for the progressive loss of lung function that is the major cause of morbidity and mortality in CF (<a href="./references#CD002201-bbs2-0041" title="KonstanMW . Treatment of airway inflammation in cystic fibrosis. Current Opinion in Pulmonary Medicine1996;2(6):452‐6. ">Konstan 1996</a>). In response to lung infections, with organisms such as <i>Pseudomonas aeruginosa</i>, neutrophils (white blood cells) accumulate within the airways, producing proteolytic enzymes and oxidants which mediate the inflammatory response (<a href="./references#CD002201-bbs2-0048" title="WilmottRW , Khurana‐HershuiG , StarkJM . Current concepts on pulmonary host defence mechanisms in children. Current Opinion in Pediatrics2000;12(3):187‐93. ">Wilmott 2000</a>). These neutrophils contribute to the thick and viscous secretions characteristic of CF, leading to mucus plugging of the smaller airways and further cycles of infection and inflammation. Treatment with anti‐inflammatory drugs, including corticosteroids (<a href="./references#CD002201-bbs2-0028" title="ChengK , AshbyD , SmythR . Oral steroids for cystic fibrosis. Cochrane Database of Systematic Reviews1999, Issue 4. [DOI: 10.1002/14651858.CD000407] ">Cheng 1999</a>; <a href="./references#CD002201-bbs2-0026" title="UK CFTrust . CF Trust Factsheet. Steroid treatment in cystic fibrosis. www.cysticfibrosis.org.uk/˜/media/documents/life‐with‐cf/publications/factsheets/factsheet‐steroid‐treatment‐2016.ashx (accessed 10 January 2020). ">CF Trust 2015</a>) and non‐steroidal anti‐inflammatory agents (<a href="./references#CD002201-bbs2-0042" title="LandsLC , StanojevicS . Oral non‐steroidal anti‐inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD001505.pub2] ">Lands 2007</a>), have been shown to have some benefit. </p> </section> <section id="CD002201-sec-0018"> <h3 class="title" id="CD002201-sec-0018">Description of the intervention</h3> <p>Mucus may also prevent pancreatic enzymes reaching the intestine and lead to malabsorption (especially fat malabsorption), diarrhoea and failure to thrive (<a href="./references#CD002201-bbs2-0038" title="HuntB , GeddesDM . Newly diagnosed cystic fibrosis in middle and later life. Thorax1985;40(1):23‐6. ">Hunt 1985</a>; <a href="./references#CD002201-bbs2-0039" title="ImrieJ , FaganD , SturgessJ . Quantitative evaluation of the development of the exocrine pancreas in cystic fibrosis and controlled subjects. American Journal Pathology1975;95(3):697‐708. ">Imrie 1975</a>). The importance of growth and nutrition on survival in CF is well established (<a href="./references#CD002201-bbs2-0030" title="CoreyM , McLaughlinFJ , WilliamsM , LevisonH . A comparison of survival, growth and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of Clinical Epidemiology1998;41(6):583‐91. ">Corey 1998</a>; <a href="./references#CD002201-bbs2-0031" title="DodgeJA . Nutritional requirement in cystic fibrosis: a review. Journal of Pediatric Gastroenterology Nutrition1988;7(Suppl 1):S8‐11. ">Dodge 1988</a>; <a href="./references#CD002201-bbs2-0034" title="GaskinK , GurwitzD , DurieP , CoreyM , LevisonH , ForstnerG . Improved respiratory prognosis in patients with normal fat absorption. Journal of Pediatrics1982;100(6):857‐62. ">Gaskin 1982</a>). Dietary strategies concentrate upon providing a high energy and high protein diet, together with pancreatic enzyme replacement therapy (<a href="./references#CD002201-bbs2-0027" title="UK CFTrust . CF Trust Consensus Documents: Nutritional Management of Cystic Fibrosis. September 2016. www.cysticfibrosis.org.uk/˜/media/documents/the‐work‐we‐do/care/consensus‐documents‐with‐old‐address/nutritional‐management‐of‐cystic‐fibrosis‐sep‐16.ashx?la=en (accessed 10 January 2020). ">CF Trust 2016</a>). Despite this, there are many people with CF with sub‐optimal nutritional absorption who continue to require fat soluble vitamins on a daily basis (<a href="./references#CD002201-bbs2-0024" title="BenabdeslamH , GarciaI , BellonG , GillyR , RevolA . Biochemical assessment of the nutritional status of cystic fibrosis patients treated with pancreatic enzyme extracts. American Journal of Human Nutrition1998;67(5):912‐8. ">Benabdeslam 1998</a>; <a href="./references#CD002201-bbs2-0027" title="UK CFTrust . CF Trust Consensus Documents: Nutritional Management of Cystic Fibrosis. September 2016. www.cysticfibrosis.org.uk/˜/media/documents/the‐work‐we‐do/care/consensus‐documents‐with‐old‐address/nutritional‐management‐of‐cystic‐fibrosis‐sep‐16.ashx?la=en (accessed 10 January 2020). ">CF Trust 2016</a>). </p> </section> <section id="CD002201-sec-0019"> <h3 class="title" id="CD002201-sec-0019">How the intervention might work</h3> <p>It has been hypothesised that essential fatty acid deficiency may contribute to the development of respiratory disease in infants, even before clinical signs become apparent (<a href="./references#CD002201-bbs2-0043" title="Lloyd‐StillJD , BibusDM , PowersCA , JohnsonSB , HolmanRT . Essential fatty acid deficiency and predisposition to lung disease in cystic fibrosis. Acta Paediatrica1996;85(12):1426‐32. ">Lloyd‐Still 1996</a>). Furthermore, animal models suggest that phenotypic changes in the CF‐affected organs of lung, pancreas and intestine may be due to a defect in essential polyunsaturated fatty acid metabolism (<a href="./references#CD002201-bbs2-0033" title="FreedmanSD , AlvarezJG . Pathogenesis of pancreatic disease in cystic fibrosis. Pediatric Pulmonology1999;Suppl 19:129. ">Freedman 1999</a>). </p> <p>In humans, the polyunsaturated fatty acids (PUFA) linoleic acid (18:2 omega‐6, or n‐6) and alpha‐linolenic (18:3 omega‐3, or n‐3) are 'essential' for normal growth and function; the only source is dietary. The nomenclature refers to their chemical structure. </p> <p>Research into the omega‐3 series of essential polyunsaturated fatty acids stems from the observation that the native Inuit (Eskimo) of Greenland (who consume a traditional diet rich in fish oils) have a very low incidence of some of the chronic inflammatory immune‐based disorders commonly found in Europe and North America (<a href="./references#CD002201-bbs2-0029" title="CorcoranAC , RabinowitchIM . A study of the blood lipids and blood proteins in Canadian Eastern Arctic Eskimos. Biochemistry Journal1937;31:343‐8. ">Corcoran 1937</a>; <a href="./references#CD002201-bbs2-0044" title="OsterudB , ElvevollE , BarstadH , BroxJ , HalvorsenH , LiaK , et al. Effect of marine oils supplementation on coagulation and cellular activation in whole blood. Lipids1995;30(12):1111‐8. ">Osterud 1995</a>). Fish oils are the richest dietary source of the metabolically active omega‐3 fatty acid derivatives eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA); however alternative and novel sources are currently being researched. Omega‐3 fatty acids have been shown to play an important role in the integrity of cellular membranes, where they exert a profoundly anti‐inflammatory response. Some of the beneficial effects of omega‐3 fatty acids on inflammatory disease can be explained by a decrease in the production of pro‐inflammatory metabolites from the omega‐6 fatty acid family and an increase in the biologically less‐active omega‐3 end products (<a href="./references#CD002201-bbs2-0035" title="GazsoA , KalimanJ , HorrobinDF , SinzingerH . Effects of omega‐3 fatty acids on the prostaglandin system in healthy probands. Wiener Klinische Wochenschrift1989;101(8):283‐8. ">Gaszo 1989</a>). Studies suggest that these fatty acids can exert anti‐inflammatory effects which may benefit a range of chronic inflammatory diseases, including CF. </p> </section> <section id="CD002201-sec-0020"> <h3 class="title" id="CD002201-sec-0020">Why it is important to do this review</h3> <p>As has been discussed above, the absorption of fatty acids may be impaired in people with CF for a number of reasons and it is therefore possible that supplementation with omega‐3 fatty acids may prove to be an effective treatment although details of dosage and administration remain to be elucidated. This is an update of previous versions of the review (<a href="./references#CD002201-bbs2-0049" title="Beckles‐WillsonNNR , ElliottT , EverardMML . Omega‐3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD002201.pub2] ">Beckles‐Willson 2002</a>; <a href="./references#CD002201-bbs2-0050" title="OliverC , EverardM , N'DiayeT . Omega‐3 fatty acids (from fish oils) for cystic fibrosis. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD002201.pub2] ">Oliver 2010</a>; <a href="./references#CD002201-bbs2-0051" title="OliverC , JahnkeN . Omega‐3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews2011, Issue 8. [DOI: 10.1002/14651858.CD002201.pub3] ">Oliver 2011</a>; <a href="./references#CD002201-bbs2-0052" title="OliverC , WatsonH . Omega‐3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD002201.pub4] ">Oliver 2013</a>; <a href="./references#CD002201-bbs2-0053" title="OliverC , WatsonH . Omega‐3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews2016, Issue 1. [DOI: 10.1002/14651858.CD002201.pub5] ">Oliver 2016</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002201-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002201-sec-0021"></div> <p>To determine whether there is evidence that omega‐3 polyunsaturated fatty acid supplementation reduces morbidity and mortality. To identify any adverse events associated with omega‐3 polyunsaturated fatty acid supplementation in CF. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002201-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002201-sec-0022"></div> <section id="CD002201-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002201-sec-0024"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), quasi‐randomised trials, and cross‐over trials.</p> </section> <section id="CD002201-sec-0025"> <h4 class="title">Types of participants</h4> <p>People with CF, of any age and severity, diagnosed clinically and by sweat or genetic testing. </p> </section> <section id="CD002201-sec-0026"> <h4 class="title">Types of interventions</h4> <p>Dietary supplementation of omega‐3 essential fatty acids of any dosage, frequency and duration compared with placebo in people with CF. The supplements contain omega‐3 fatty acids in the form of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), or both. Studies were included if they compared the effect of this intervention with a placebo with low omega‐3 or omega‐6 fatty acid content, such as olive oil. </p> </section> <section id="CD002201-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD002201-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD002201-list-0001"> <li> <p>Number of respiratory exacerbations including:</p> <ol id="CD002201-list-0002"> <li> <p>hospitalisations</p> </li> <li> <p>number of courses of antibiotics given (oral and intravenous) (moved from secondary outcomes in a post hoc change) </p> </li> </ol> </li> <li> <p>Adverse events and dropouts</p> </li> <li> <p>Lung function including</p> <ol id="CD002201-list-0003"> <li> <p>per cent predicted forced expiratory volume in one second (FEV<sub>1</sub>) </p> </li> <li> <p>forced vital capacity (FVC)</p> </li> </ol> </li> </ol> </p> </section> <section id="CD002201-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD002201-list-0004"> <li> <p>Quality of life</p> </li> <li> <p>Number of deaths</p> </li> <li> <p>Clinical variables including indices of growth or nutrition</p> </li> <li> <p>Bronchial responsiveness as measured by any provocation testing</p> </li> <li> <p>Biochemical markers of essential fatty acid status including plasma, platelet and erythrocyte (red blood cell) levels of EPA or DHA or both, plus omega‐3 to omega‐6 fatty acid ratio </p> </li> </ol> </p> </section> </section> </section> <section id="CD002201-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not restrict the searches by language, year or publication status.</p> <section id="CD002201-sec-0031"> <h4 class="title">Electronic searches</h4> <p>Relevant studies were identified from the Group's cystic fibrosis trials register using the terms: omega‐3 fatty acids. </p> <p>The Group's Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching through the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. For full details of all searching activities for the register, please see the relevant sections of the <a href="https://cfgd.cochrane.org/our-specialised-trials-registers" target="_blank">website</a>. </p> <p>In addition, the original review team performed electronic searches of CINAHL and EMBASE (from 1995 to April 2007) (<a href="./appendices#CD002201-sec-0092">Appendix 1</a>). When the current review team took on this review, these searches were no longer run. The current review team have searched the online registries clinicaltrials.gov and the WHO ICTRP (Appendix 2). </p> <p>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 01 April 2020. </p> </section> <section id="CD002201-sec-0032"> <h4 class="title">Searching other resources</h4> <p>The reference lists of all studies identified have also been checked. The first author of each paper was contacted and invited to identify any other published or unpublished studies that might be relevant. </p> </section> </section> <section id="CD002201-sec-0033"> <h3 class="title" id="CD002201-sec-0033">Data collection and analysis</h3> <section id="CD002201-sec-0034"> <h4 class="title">Selection of studies</h4> <p>For the current version of the review, two authors (HW, CS) independently selected studies to be included in the review. If there had been any disagreement, they would have resolved this by discussion. </p> </section> <section id="CD002201-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>The two authors (HW, CS for 2019 update onwards) independently extracted data onto data acquisition forms. Authors discussed all stages of data extraction and interpretation and there were no disagreements to resolve. </p> <p>They grouped outcome data into those measured at six and 12 weeks and at six and 12 months from baseline. For future updates of this review, if data are reported at any other time periods, they will consider reporting these as well. </p> <p>Since hospitalisations are often used as a marker for respiratory exacerbations, if the authors include a study which reports hospitalisations in addition to or instead of exacerbations, they will include this information in the review under the first primary outcome ‘Number of respiratory exacerbations’. </p> </section> <section id="CD002201-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (HW, CS) assessed each trial using the domain‐based evaluation as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD002201-bbs2-0037" title="HigginsJP , AltmanDG , Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>The authors assessed the following domains as low risk of bias, unclear risk of bias or high risk of bias. </p> <p> <ol id="CD002201-list-0005"> <li> <p>Randomisation (low risk ‐ random number table, computer‐generated lists or similar methods; unclear risk ‐ described as randomised, but no details given; high risk ‐ e.g. alternation, the use of case record numbers, and dates of birth or day of the week). </p> </li> <li> <p>Concealment of allocation (low risk ‐ e.g. list from a central independent unit, on‐site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed opaque envelopes; unclear risk ‐ not described; high risk ‐ if allocation sequence was known to, or could be deciphered by the investigators who assigned participants or if the trial was quasi‐randomised). </p> </li> <li> <p>Blinding (of participants, personnel and outcome assessors) (low risk ‐ e.g. there was no blinding, but we judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding, or at least outcome assessors were blinded; unclear risk ‐ not described; high risk ‐ e.g. no or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding, or blinding was attempted, but likely to have been broken). </p> </li> <li> <p>Incomplete outcome data (Whether investigators used an intention‐to‐treat analysis) (low risk ‐ e.g. no missing data, or missing data have been imputed using appropriate methods; unclear risk ‐ e.g. insufficient reporting of attrition/exclusions; high risk ‐ e.g. reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups). </p> </li> <li> <p>Selective outcome reporting (low risk ‐ e.g. the study protocol is available and all of the studies pre‐specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre‐specified way; unclear risk ‐ e.g. insufficient information to permit judgement; high risk ‐ e.g. not all of the study's pre‐specified primary outcomes have been reported). </p> </li> <li> <p>Other potential sources of bias (low risk ‐ the study appears to be free of other sources of bias; unclear risk ‐ e.g. insufficient information to assess whether an important risk of bias exists; high risk ‐ e.g. had a potential source of bias related to the specific study design used, or had extreme baseline imbalance). </p> </li> </ol> </p> <p>The authors compared assessments and resolved any inconsistencies by discussion.</p> </section> <section id="CD002201-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>For binary outcomes, the authors have calculated a pooled estimate of the treatment effect for each outcome across studies using the odds ratio (OR) (the odds of an outcome among treatment allocated participants to the corresponding odds among controls) and 95% confidence intervals (CIs). For continuous outcomes, they recorded either mean change from baseline for each group or mean post‐treatment or intervention values and standard deviations for each group. Then, where appropriate, they have calculated a pooled estimate of treatment effect by calculating the mean difference (MD) and 95% CIs. </p> </section> <section id="CD002201-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>When conducting a meta‐analysis combining results from cross‐over studies the authors planned to use the methods recommended by Elbourne (<a href="./references#CD002201-bbs2-0032" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). Limited availability of data would mean, we would only able to either use only the first‐arm data or to treat the cross‐over studies as if they are parallel studies. Elbourne states that this approach will produce conservative results as it does not take into account within‐patient correlation (<a href="./references#CD002201-bbs2-0032" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). Also each participant will appear in both the treatment and control group, so the two groups will not be independent. For one cross‐over study included in the review, the authors were not able to access the first‐arm data, and so they have treated the study as if it were parallel (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). If they are able to obtain a correlation co‐efficient for future updates of this review, they will analyse the data more appropriately. </p> </section> <section id="CD002201-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>For future updates of the review, in order to allow an intention‐to‐treat analysis, the authors will seek data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up. </p> <p>The review authors have requested missing data from the primary investigators of two studies on several occasions (<a href="./references#CD002201-bbs2-0010" title="KoletzkoB , Tuxen‐MengedohtM , MullerI , DemmelmairH , SternM , SteffanJ . Polyunsaturated fatty acids improve outcome of cystic fibrosis patients. 13th International Cystic Fibrosis Conference; 2000 June 4‐8; Stockholm. 2000:78. [CFGD Register: GN65b] Tuxen‐MengedohtM , KoletzkoB , DemmelmairH , KnappV , SternM . Fish oil therapy in cystic fibrosis (CF): A randomised clinical trial. Clinical Nutrition1999;18(Suppl 1):54. [CFGD Register: GN65a] Tuxen‐MengedohtM , KoletzkoB , MullerI , DemmelmairH , KnappV , SternM , et al. Fish‐oil therapy in mucoviscidosis: A randomised double‐blind study [Fischol‐Therapie bei Mukiviszidose: Eine randomisierte Doppelblindstudie]. Monatsschrift Fur Kinderheilkunde1999;147(Suppl 2):107. [CFGD Register: GN65c] ">Koletzko 2000</a>; <a href="./references#CD002201-bbs2-0020" title="RomanoL , GandinoM , FioreP , ShepherdD , CasciaroR , CocciaC , et al. Study on feasibility and results of midterm dietary supplementation in omega‐3 fatty acids. 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:167. [CFGD Register: GN67] ">Romano 1997</a>); however, up until 2007 there was no response. They have therefore excluded these studies and do not plan to contact the authors of them again in the future. </p> <p>We required and requested additional data from the authors of one study regarding the detail of the protocol and the results table (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). We also required additional data to analyse comparisons between the two CF groups in the included Henderson study; however, a reply from the author has not been received to date (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). </p> </section> <section id="CD002201-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>For future updates of the review, if the authors are able to present combined data from a sufficient number of studies (at least four), they will test for heterogeneity between study results using the I² statistic (<a href="./references#CD002201-bbs2-0036" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). For this measure of consistency of results across studies values range from 0% to 100%. They plan to categorise heterogeneity in a simple way such that if the I² value is around 25% or below, they consider heterogeneity to be low; if the value is around 50%, they will consider it moderate; if the value is around 75% or above, they will consider it high. </p> </section> <section id="CD002201-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>The review authors checked that the study investigators reported on all the outcomes they stated they planned to measure in the full publications of their studies. When the authors include a sufficient number of studies, they will attempt to assess whether this review is subject to publication bias by using a funnel plot. If they detect asymmetry, they will explore causes other than publication bias. </p> <p>The review authors also checked for selective outcome reporting by comparing the protocols of the included studies (where available) to the final paper to ensure that the investigators reported all outcomes measured. If the study protocols were not available, the review authors compared the 'Methods' section to the 'Results' section in the final published paper. </p> </section> <section id="CD002201-sec-0042"> <h4 class="title">Data synthesis</h4> <p>The review authors have analysed their data using a fixed‐effect model. However, if for future updates they identify moderate or high degrees of heterogeneity, they will analyse the data using a random‐effects model. </p> </section> <section id="CD002201-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If the authors identify moderate or high degrees of heterogeneity and they are able to included sufficient studies in the review (at least four), they plan to investigate this by performing subgroup analyses (e.g. children versus adults and severity of existing lung disease). </p> </section> <section id="CD002201-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>If the authors identify moderate or high degrees of heterogeneity and they are able to include sufficient studies in the review, they also plan a sensitivity analysis comparing trials with or without cross‐over design. </p> <section id="CD002201-sec-0045"> <h5 class="title">Summary of findings tables</h5> <p>In line with current Cochrane guidance, at the 2020 update the authors have presented the outcomes listed below in a summary of findings table (Summary of findings table 1). The authors selected these outcomes based on relevance to clinicians and consumers. </p> <p> <ul id="CD002201-list-0006"> <li> <p>Number of respiratory exacerbations</p> </li> <li> <p>Adverse events</p> </li> <li> <p>FEV<sub>1</sub> % predicted </p> </li> <li> <p>FVC % predicted</p> </li> <li> <p>Clinical variables of growth and nutrition</p> </li> <li> <p>Biochemical markers of essential fatty acid status</p> </li> </ul> </p> <p>For each outcome we report the illustrative risk with and without the intervention, magnitude of effect (RR or MD), numbers of trials and participants addressing each outcome and a grade of the overall quality of the body of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) with comments (<a href="./references#CD002201-bbs2-0045" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2011a</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002201-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002201-sec-0046"></div> <section id="CD002201-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD002201-sec-0048"> <h4 class="title">Results of the search</h4> <p>The literature searches identified 23 studies, including five clinical trials identified from online trials registries. Five studies involving 106 participants with CF met the inclusion criteria (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). For the 2020 update, one abstract previously listed as awaiting classification was a related reference to a full published study which met the inclusion criteria (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). One further abstract previously listed under awaiting classification did not have sufficient information to include it in the review; we contacted the author for further information but no response was received, therefore it was excluded (<a href="./references#CD002201-bbs2-0018" title="O'SullivanB , BakerD , BorowitzD , ComeauA , ClevelandR , FreedmanS . The effect of formula fortified with docosahexaenoic acid (DHA) on infants with CF. Pediatric Pulmonology2011;46 Suppl 34:401. [Abstract no.: 519; CFGD Register: GN229; ] ">O'Sullivan 2011</a>). A total of 13 studies published as abstracts or full papers were excluded with reasons; (<a href="./references#CD002201-bbs2-0006" title="AlicandroG , FaelliN , GagliardiniR , SantiniB , MagazzuG , BiffiA , et al. A randomized placebo‐controlled study on high‐dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids2013;88(2):163‐9. [CFGD Register: GN118d; ] AlicandroG , GagliardiniR , RiseP , SantiniB , BiffiA , TirelliS , et al. Oral DHA supplementation in children with CF: a randomized placebo‐controlled study. Pediatric Pulmonology2011;46 Suppl 34:394. [Abstract no.: 499; CFGD Register: GN118c; ] AlicandroG , GagliardiniR , SantiniB , RiseP , BiffiA , TirelliAS , et al. Oral DHA supplementation in children with cystic fibrosis: a randomized placebo‐controlled study. Journal of Cystic Fibrosis2011;10 Suppl 1:S74. [Abstract no.: 290; CFGD Register: GN118b; ] ColomboC , DaccoV , SantiniB , GarliardiniR , LoiS , CasartelliM , et al. DHA supplementation in children affected by cystic fibrosis: an Italian, multicentre clinical trial. Pediatric Pulmonology2008;43 Suppl 31:427. [CFGD Register: GN118a] ">Alicandro 2013</a>; <a href="./references#CD002201-bbs2-0007" title="ChristopheA , RobberechtE , FranckxH . Effects of two different dietary supplements on eicosanoid precursor fatty acids in cystic fibrosis. 11th International Cystic Fibrosis Congress, Dublin, Ireland. 1992:MP76. [CFGD Register: GN54] ">Christophe 1992</a>; <a href="./references#CD002201-bbs2-0009" title="KatzDP , MannerT , FurstP , AskanaziJ . The use of an intravenous fish oil emulsion enriched with omega‐3 fatty acids in patients with cystic fibrosis. Nutrition1996;12(5):334‐9. [CFGD Register: GN66a] MannerT , GuidaL , KatzDP , AskanaziJ , SchlotzerE , WiesseS . Parenteral fish oil administration in patients with cystic fibrosis. Clinical Nutrition1992;11(11):40. [CFGD Register: GN66c] MannerT , KatzDP , AskanaziJ , SchlotzerE , FurstP . Parenteral fish oil administration in patients with cystic fibrosis. 17th Clinical Congress of ASPEN (American Society for Parenteral and Enteral Nutrition). 1993:440. [CFGD Register: GN66b] ">Katz 1996</a>; <a href="./references#CD002201-bbs2-0010" title="KoletzkoB , Tuxen‐MengedohtM , MullerI , DemmelmairH , SternM , SteffanJ . Polyunsaturated fatty acids improve outcome of cystic fibrosis patients. 13th International Cystic Fibrosis Conference; 2000 June 4‐8; Stockholm. 2000:78. [CFGD Register: GN65b] Tuxen‐MengedohtM , KoletzkoB , DemmelmairH , KnappV , SternM . Fish oil therapy in cystic fibrosis (CF): A randomised clinical trial. Clinical Nutrition1999;18(Suppl 1):54. [CFGD Register: GN65a] Tuxen‐MengedohtM , KoletzkoB , MullerI , DemmelmairH , KnappV , SternM , et al. Fish‐oil therapy in mucoviscidosis: A randomised double‐blind study [Fischol‐Therapie bei Mukiviszidose: Eine randomisierte Doppelblindstudie]. Monatsschrift Fur Kinderheilkunde1999;147(Suppl 2):107. [CFGD Register: GN65c] ">Koletzko 2000</a>; <a href="./references#CD002201-bbs2-0011" title="KurlandskyLE , BenninkMR , WebbPM , UlrichPJ , BaerLJ . The absorption and effect of dietary supplementation with omega‐3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatric Pulmonology1994;18(4):211‐7. [CFGD Register: GN46] ">Kurlandsky 1994</a>; <a href="./references#CD002201-bbs2-0012" title="Lloyd‐StillJ , PowersC , HoffmanD , ArterburnL , BenisekD , LesterL . Bioavailability and safety of an algal DHA triglyceride in cystic fibrosis. Pediatric Research2001;49(4 Suppl):455a. [CFGD Register: GN92d] Lloyd‐StillJ , PowersC , HoffmanD , Boyd‐TrullK , LesterL , BenisekD , et al. A randomised controlled study examining the bioavailability and safety of an algal docosahexaenoic acid (DHA) triacylglycerol in cystic fibrosis patients. Pediatric Pulmonology2004;38(Suppl 27):331. [CFGD Register: GN92c] Lloyd‐StillJ , PowersC , HoffmanD , Boyd‐TrullK , LesterL , BenisekD , et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomised controlled study. Nutrition2006;22(1):36‐46. [CFGD Register: GN92e] Lloyd‐StillJ , PowersC , HoffmanD , Boyd‐trullK , ArterburnL , BenisekD , et al. Blood and tissue essential fatty acids after docosahexaenoic acid supplementation in cystic fibrosis. Pediatric Pulmonology2001;32(Suppl 22):263. [CFGD Register: GN92b] PowersCA , Lloyd‐StillJ , HoffmanD , ArteburnL , BenisekD , LesterL . Lipid soluble antioxidant status during supplementation with algal docosahexaenoic acid triglyceride in CF. Abstracts of the 24th European Cystic Fibrosis Conference. 2001:P133. [CFGD Register: GN92a] ">Lloyd‐Still 2006</a>; <a href="./references#CD002201-bbs2-0017" title="O'ConnorMG , ThomsenK , BrownRF , LaposataM , SeegmillerA . Elevated prostaglandin e metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;113:46‐9. [CFGD Register: GN250b] O'connorMG , ThomsenK , BrownRF , LaposataM , SeegmillerAC . DHA supplementation in pediatric CF patients: a randomized, double‐blind clinical trial.. Pediatric Pulmonology. 2015; Vol. Suppl 34:401. [Abstract no.: 582; CFGD Register: GN250a] ">O'Connor 2016</a>; <a href="./references#CD002201-bbs2-0018" title="O'SullivanB , BakerD , BorowitzD , ComeauA , ClevelandR , FreedmanS . The effect of formula fortified with docosahexaenoic acid (DHA) on infants with CF. Pediatric Pulmonology2011;46 Suppl 34:401. [Abstract no.: 519; CFGD Register: GN229; ] ">O'Sullivan 2011</a>; <a href="./references#CD002201-bbs2-0019" title="PastorO , Guzman‐LafuenteP , SernaJ , Munoz‐HernandezM , Lopez NeyraA , Garcia‐RozasP , et al. A comprehensive evaluation of omega‐3 fatty acid supplementation in cystic fibrosis patients using lipidomics. Journal of Nutritional Biochemistry2019;63:197‐205. [CFGD Register: GN277; DOI: 10.1016/j.jnutbio.2018.09.026] ">Pastor 2019</a>; <a href="./references#CD002201-bbs2-0020" title="RomanoL , GandinoM , FioreP , ShepherdD , CasciaroR , CocciaC , et al. Study on feasibility and results of midterm dietary supplementation in omega‐3 fatty acids. 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:167. [CFGD Register: GN67] ">Romano 1997</a>; <a href="./references#CD002201-bbs2-0021" title="StarlingMB , ElliotRB . EPA and cystic fibrosis. Excerpta Medica, Asia Pacific Congress Series. 10th International Cystic Fibrosis Congress. 1988:74. [CFGD Register: GN59] ">Starling 1988</a>; <a href="./references#CD002201-bbs2-0022" title="VanBiervlietS , DevosM , DelhayeJ , VanBiervlietJ , RobberechtE , ChristopheA . Oral DHA supplementation in F508 homozygous cystic fibrosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids2008;78(2):109‐15. [CFGD Register: GN116] ">van Biervliet 2008</a>; <a href="./references#CD002201-bbs2-0023" title="VericelE , MazurS , ColasR , DelaupV , CalzadaC , ReixP , et al. Moderate intake of docosahexaenoic acid raises plasma and platelet vitamin E. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;115:41‐7. [CFGD Register: GN264; DOI: 10.1016/j.plefa.2016.10.008] ">Vericel 2019</a>). The five clinical trials identified from online trials registries were also excluded; (<a href="./references#CD002201-bbs2-0008" title="EUCTR2006‐004155‐38‐BE . Biochemical effects of a long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis ‐ omega 3 study. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2006‐004155‐38‐BE (first received 23 September 2008). ">EUCTR2006‐004155038‐BE</a>, <a href="./references#CD002201-bbs2-0013" title="NCT02518672 . Pro‐resolving effect of MAG‐DHA in cystic fibrosis (PREMDIC). clinicaltrials.gov/ct2/show/NCT02518672 (first received 10 August 2015). ">NCT02518672</a>; <a href="./references#CD002201-bbs2-0014" title="NCT02646995 . Lipid formulation to increase the bioavailabilty of fatty acids in cystic fibrosis (CF) patients. clinicaltrials.gov/ct2/show/NCT02646995 (first received 6 January 2016). ">NCT02646995</a>; <a href="./references#CD002201-bbs2-0015" title="NCT02690857 . Study of docosahexanoic acid in patients with cystic fibrosis (CF) (OMEGAMUCO). clinicaltrials.gov/ct2/show/NCT02690857 (first received 24 Feb 2016). ">NCT02690857</a>; <a href="./references#CD002201-bbs2-0016" title="NCT03045198 . Effect of azithromycin on fatty acids in CF. clinicaltrials.gov/ct2/show/NCT03045198 (first received 07 February 2017). ">NCT03045198</a>). Please also see the PRISMA diagram generated for this process (<a href="#CD002201-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD002201-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow (PRISMA) diagram" data-id="CD002201-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow (PRISMA) diagram</p> </div> </div> </div> </section> <section id="CD002201-sec-0049"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD002201-sec-0103" title="">Characteristics of included studies</a>. </p> <section id="CD002201-sec-0050"> <h5 class="title">Study characteristics</h5> <p>All five included studies were RCTs (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Study duration varied from six weeks (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>) to 12 months (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). The number of participants varied from 12 (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>) to 43 (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> <p>Three studies were of parallel design (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). One study split participants into two groups who received either an omega‐3 PUFA supplement or placebo (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). Henderson split participants into four groups, two of which were in people without CF, we did not consider information from the groups without CF, as healthy participants are not eligible for inclusion in the review. The two groups of participants with CF received either active supplement or placebo (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). The third study randomised participants to three groups: one group received a high omega‐3 fatty acid blend (EPA and DHA); one group received a fatty acid blend containing predominantly omega‐6 fatty acids (linoleic acid (LA), arachidonic acid (AA)); the control group received a high saturated‐fatty acid (SFA) blend. We did not consider results from the group receiving the omega‐6 fatty acid intervention as this intervention was eligible for inclusion in the review (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> <p>Two studies were of cross‐over design (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Lawrence found a carry‐over effect despite a 12‐week washout period, therefore, only the results from the 16 participants who completed the first six‐week period of the study were used (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Panchaud did not include a washout period and we have treated this study as if it had a parallel design (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> <section id="CD002201-sec-0051"> <h5 class="title">Participants</h5> <p>All five studies included both children and adults (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>), although only two studies included older adults, where the age range was stated as up to 41 years (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>), and 30.4 years (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). None of the studies were very large; the number of participants in each trial ranged from 12 (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>) to 43 (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). There were more males in four of the studies (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>), but one more female than males in the Keen study (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> <p>Four studies described participants as having pancreatic insufficiency (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Pancreatic status was not explicitly specified in one study (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Two studies stated that participants were chronically infected with <i>Pseudomonas aeruginosa</i> (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Keen additionally described participants as having severe mutations (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). One study described participants as homozygous for the Delta F508 mutation and already undergoing azithromycin treatment for more than three months (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> </section> <section id="CD002201-sec-0052"> <h5 class="title">Interventions</h5> <p>Two studies compared omega‐3 fatty acids to olive oil control for a six‐week treatment period (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). One study compared omega‐3 fatty acids to placebo control for a six‐month treatment period (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Another study compared essential fatty acid supplementation to a placebo for a three‐month treatment period (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). One study compared omega‐3 fatty acids to placebo control for a 12‐month treatment period (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> <p>The dose and form of omega‐3 fatty acids differed between the studies. Henderson used four 1 g capsules of fish oil, twice daily (containing a daily dose of 3.2 g EPA and 2.2 g DHA) (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). Lawrence used fish‐oil capsules containing a daily total of 2.7 g EPA (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Panchaud used a liquid PUFA mixture containing 0.2 g EPA and 0.1 g DHA per 200 mL (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). The volume of supplementation was determined according to participant's weight; intake ranged from 200 mg to 600 mg EPA and 100 mg to 300 mg DHA per day. Keen used a customised fatty acid blend containing 21.27 % mmol EPA and 6.99 % mmol DHA and participants received 50 mg per kg body weight per day (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). Hanssens used an omega‐3 PUFA supplementation containing 300 mg omega‐3 triglycerides from fish oil, specifically providing 100 mg DHA and 150 mg EPA. The total daily dose was calculated to correspond to 60 mg/kg body weight (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> </section> <section id="CD002201-sec-0053"> <h5 class="title">Outcomes</h5> <p>All five studies reported on adverse events (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>) and three on deaths (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Two studies reported on changes in haematological indices (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Two studies presented data on serum fatty acid content (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>) and two on changes in in vitro neutrophil chemotaxis (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Three studies reported responses to inflammatory markers and nutritional indices (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Four studies reported on lung function (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Two studies reported on change in the number of respiratory exacerbations or antibiotic usage (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </section> </section> <section id="CD002201-sec-0054"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD002201-sec-0104" title="">Characteristics of excluded studies</a>. </p> <p>13 studies have been excluded from the review. One study used parenteral (via blood stream), not enteral (oral) supplementation with omega‐3 fatty acids (<a href="./references#CD002201-bbs2-0009" title="KatzDP , MannerT , FurstP , AskanaziJ . The use of an intravenous fish oil emulsion enriched with omega‐3 fatty acids in patients with cystic fibrosis. Nutrition1996;12(5):334‐9. [CFGD Register: GN66a] MannerT , GuidaL , KatzDP , AskanaziJ , SchlotzerE , WiesseS . Parenteral fish oil administration in patients with cystic fibrosis. Clinical Nutrition1992;11(11):40. [CFGD Register: GN66c] MannerT , KatzDP , AskanaziJ , SchlotzerE , FurstP . Parenteral fish oil administration in patients with cystic fibrosis. 17th Clinical Congress of ASPEN (American Society for Parenteral and Enteral Nutrition). 1993:440. [CFGD Register: GN66b] ">Katz 1996</a>). Five studies compared omega‐3 supplementation with a large omega‐6 fatty acid source, rather than a neutral placebo that contains relatively little omega‐3 or omega‐6 fatty acid such as olive oil. One study compared omega‐3 supplementation with borache oil (<a href="./references#CD002201-bbs2-0007" title="ChristopheA , RobberechtE , FranckxH . Effects of two different dietary supplements on eicosanoid precursor fatty acids in cystic fibrosis. 11th International Cystic Fibrosis Congress, Dublin, Ireland. 1992:MP76. [CFGD Register: GN54] ">Christophe 1992</a>), two studies with sunflower oil (<a href="./references#CD002201-bbs2-0011" title="KurlandskyLE , BenninkMR , WebbPM , UlrichPJ , BaerLJ . The absorption and effect of dietary supplementation with omega‐3 fatty acids on serum leukotriene B4 in patients with cystic fibrosis. Pediatric Pulmonology1994;18(4):211‐7. [CFGD Register: GN46] ">Kurlandsky 1994</a>; <a href="./references#CD002201-bbs2-0022" title="VanBiervlietS , DevosM , DelhayeJ , VanBiervlietJ , RobberechtE , ChristopheA . Oral DHA supplementation in F508 homozygous cystic fibrosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids2008;78(2):109‐15. [CFGD Register: GN116] ">van Biervliet 2008</a>) one study with germ oil (<a href="./references#CD002201-bbs2-0006" title="AlicandroG , FaelliN , GagliardiniR , SantiniB , MagazzuG , BiffiA , et al. A randomized placebo‐controlled study on high‐dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins, Leukotrienes and Essential Fatty Acids2013;88(2):163‐9. [CFGD Register: GN118d; ] AlicandroG , GagliardiniR , RiseP , SantiniB , BiffiA , TirelliS , et al. Oral DHA supplementation in children with CF: a randomized placebo‐controlled study. Pediatric Pulmonology2011;46 Suppl 34:394. [Abstract no.: 499; CFGD Register: GN118c; ] AlicandroG , GagliardiniR , SantiniB , RiseP , BiffiA , TirelliAS , et al. Oral DHA supplementation in children with cystic fibrosis: a randomized placebo‐controlled study. Journal of Cystic Fibrosis2011;10 Suppl 1:S74. [Abstract no.: 290; CFGD Register: GN118b; ] ColomboC , DaccoV , SantiniB , GarliardiniR , LoiS , CasartelliM , et al. DHA supplementation in children affected by cystic fibrosis: an Italian, multicentre clinical trial. Pediatric Pulmonology2008;43 Suppl 31:427. [CFGD Register: GN118a] ">Alicandro 2013</a>) and one study with corn/soy oil as placebo (<a href="./references#CD002201-bbs2-0012" title="Lloyd‐StillJ , PowersC , HoffmanD , ArterburnL , BenisekD , LesterL . Bioavailability and safety of an algal DHA triglyceride in cystic fibrosis. Pediatric Research2001;49(4 Suppl):455a. [CFGD Register: GN92d] Lloyd‐StillJ , PowersC , HoffmanD , Boyd‐TrullK , LesterL , BenisekD , et al. A randomised controlled study examining the bioavailability and safety of an algal docosahexaenoic acid (DHA) triacylglycerol in cystic fibrosis patients. Pediatric Pulmonology2004;38(Suppl 27):331. [CFGD Register: GN92c] Lloyd‐StillJ , PowersC , HoffmanD , Boyd‐TrullK , LesterL , BenisekD , et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomised controlled study. Nutrition2006;22(1):36‐46. [CFGD Register: GN92e] Lloyd‐StillJ , PowersC , HoffmanD , Boyd‐trullK , ArterburnL , BenisekD , et al. Blood and tissue essential fatty acids after docosahexaenoic acid supplementation in cystic fibrosis. Pediatric Pulmonology2001;32(Suppl 22):263. [CFGD Register: GN92b] PowersCA , Lloyd‐StillJ , HoffmanD , ArteburnL , BenisekD , LesterL . Lipid soluble antioxidant status during supplementation with algal docosahexaenoic acid triglyceride in CF. Abstracts of the 24th European Cystic Fibrosis Conference. 2001:P133. [CFGD Register: GN92a] ">Lloyd‐Still 2006</a>). Two studies compared omega‐3 supplementation with a large omega‐6 fatty acid source (sunflower oil) rather than a neutral placebo containing relatively little omega‐3 or omega‐6 (<a href="./references#CD002201-bbs2-0017" title="O'ConnorMG , ThomsenK , BrownRF , LaposataM , SeegmillerA . Elevated prostaglandin e metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;113:46‐9. [CFGD Register: GN250b] O'connorMG , ThomsenK , BrownRF , LaposataM , SeegmillerAC . DHA supplementation in pediatric CF patients: a randomized, double‐blind clinical trial.. Pediatric Pulmonology. 2015; Vol. Suppl 34:401. [Abstract no.: 582; CFGD Register: GN250a] ">O'Connor 2016</a>; <a href="./references#CD002201-bbs2-0023" title="VericelE , MazurS , ColasR , DelaupV , CalzadaC , ReixP , et al. Moderate intake of docosahexaenoic acid raises plasma and platelet vitamin E. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;115:41‐7. [CFGD Register: GN264; DOI: 10.1016/j.plefa.2016.10.008] ">Vericel 2019</a>). One study was aimed to identify a suitable approach for monitoring the incorporation of omega‐3 fatty acids in nutritional studies and was not a comparison of omega‐3 fatty acids with control (<a href="./references#CD002201-bbs2-0019" title="PastorO , Guzman‐LafuenteP , SernaJ , Munoz‐HernandezM , Lopez NeyraA , Garcia‐RozasP , et al. A comprehensive evaluation of omega‐3 fatty acid supplementation in cystic fibrosis patients using lipidomics. Journal of Nutritional Biochemistry2019;63:197‐205. [CFGD Register: GN277; DOI: 10.1016/j.jnutbio.2018.09.026] ">Pastor 2019</a>). </p> <p>Four studies were excluded on the basis of insufficient information and a lack of response from the studies' authors (<a href="./references#CD002201-bbs2-0010" title="KoletzkoB , Tuxen‐MengedohtM , MullerI , DemmelmairH , SternM , SteffanJ . Polyunsaturated fatty acids improve outcome of cystic fibrosis patients. 13th International Cystic Fibrosis Conference; 2000 June 4‐8; Stockholm. 2000:78. [CFGD Register: GN65b] Tuxen‐MengedohtM , KoletzkoB , DemmelmairH , KnappV , SternM . Fish oil therapy in cystic fibrosis (CF): A randomised clinical trial. Clinical Nutrition1999;18(Suppl 1):54. [CFGD Register: GN65a] Tuxen‐MengedohtM , KoletzkoB , MullerI , DemmelmairH , KnappV , SternM , et al. Fish‐oil therapy in mucoviscidosis: A randomised double‐blind study [Fischol‐Therapie bei Mukiviszidose: Eine randomisierte Doppelblindstudie]. Monatsschrift Fur Kinderheilkunde1999;147(Suppl 2):107. [CFGD Register: GN65c] ">Koletzko 2000</a>; <a href="./references#CD002201-bbs2-0018" title="O'SullivanB , BakerD , BorowitzD , ComeauA , ClevelandR , FreedmanS . The effect of formula fortified with docosahexaenoic acid (DHA) on infants with CF. Pediatric Pulmonology2011;46 Suppl 34:401. [Abstract no.: 519; CFGD Register: GN229; ] ">O'Sullivan 2011</a>; <a href="./references#CD002201-bbs2-0020" title="RomanoL , GandinoM , FioreP , ShepherdD , CasciaroR , CocciaC , et al. Study on feasibility and results of midterm dietary supplementation in omega‐3 fatty acids. 21st European Cystic Fibrosis Conference; 1997; Davos. 1997:167. [CFGD Register: GN67] ">Romano 1997</a>; <a href="./references#CD002201-bbs2-0021" title="StarlingMB , ElliotRB . EPA and cystic fibrosis. Excerpta Medica, Asia Pacific Congress Series. 10th International Cystic Fibrosis Congress. 1988:74. [CFGD Register: GN59] ">Starling 1988</a>). </p> </section> </section> <section id="CD002201-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>Please see the risk of bias summary presented in the figures (<a href="#CD002201-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD002201-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002201-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002201-sec-0056"> <h4 class="title">Allocation</h4> <section id="CD002201-sec-0057"> <h5 class="title">Generation of randomisation sequence</h5> <p>All five studies were described as randomised, but only three studies gave details on the randomisation process and we graded these studies as having a low risk of bias (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). The Henderson study was randomised using a stratified randomised block design, whilst the Keen study was randomised using a random number generator (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). The Hanssens study was randomised using a randomised block design stratified according to participant weight (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). The remaining two studies did not state the randomisation technique, so were graded as having an unclear risk of bias (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> <section id="CD002201-sec-0058"> <h5 class="title">Concealment of allocation</h5> <p>Allocation concealment was graded as having an unclear risk of bias for all five studies as no details were provided in the primary papers (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> </section> <section id="CD002201-sec-0059"> <h4 class="title">Blinding</h4> <p>All five studies were described as double blind, details were provided as follows. While the capsules in the Henderson study were also not described as identical, it was stated that the placebo olive oil capsules were flavoured to obtain a slight fish taste which the review authors agreed would be sufficient to blind participants (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). In the Lawrence study, the treatment was administered as "identical olive oil capsules" (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). In the third study, the placebo treatment was not stated to be identical but it was described as the same liquid dietary supplement as the intervention but without the PUFA mixture (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). We therefore attributed a low risk of bias to each of these three studies. </p> <p>In two studies, the appearance of the capsules was not described and two of 12 participants (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>) complained of a fish smell in the omega‐3 treatment group. The appearance of the capsules is not described in Hanssens study but one participant withdrew from the study due to the fishy taste of the capsules (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). Therefore, the risk of bias in these studies is unclear (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </section> <section id="CD002201-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>In all five studies, withdrawals from the study were discussed with explanations (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Further details of these withdrawals are given in the tables (<a href="./references#CD002201-sec-0103" title="">Characteristics of included studies</a>). Only one study included all participants in the data analysis, which was performed according to the intention‐to‐treat principle and this study was judged to have a low risk of bias (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). </p> <p>The remaining four studies did not employ this approach, but did describe withdrawals from the study (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). In two studies there was a low dropout rate; in one study two out of 15 participants dropped out (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>) and in the second three out of 19 dropped out (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). We therefore assessed these two studies as having a low risk of bias. The remaining two studies were judged to have an unclear risk of bias (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). More than 15% of participants entering one study were excluded from data analysis and only results of 35 participants who completed the study were used in the review (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). In the second study, some of the data from baseline and end of treatment in the placebo and treatment groups were excluded from analysis due to "technical reasons" which were not defined (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> <section id="CD002201-sec-0061"> <h4 class="title">Selective reporting</h4> <p>We have not been able to determine any selective reporting from the final publication of four of the included studies (unclear risk of bias); however, we have not been able to compare the full study reports to the original study protocols (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> <p>The remaining study has a high risk of selective reporting bias (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). The original study protocol refers to clinical status as an outcome, however, it does not explicitly detail which clinical parameters are to be measured as specific primary and secondary outcomes. The frequency and duration of treatment with IV antibiotics is not specifically defined as a primary outcome, but in the published paper the primary finding is of a decrease in cumulative IV antibiotic duration and in number of pulmonary exacerbations at 12 months. Furthermore, these data are presented as medians for treatment and placebo groups, but without full ranges for the placebo group (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> </section> <section id="CD002201-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>There is a potential source of bias in one of the studies that did not describe the actual dose of EPA and DHA given (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). We have not been able to determine any other potential sources of bias in four of the included studies and judge there to be a low risk of bias (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> </section> <section id="CD002201-sec-0063"> <h3 class="title" id="CD002201-sec-0063">Effects of interventions</h3> <p>See: <a href="./full#CD002201-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: omega‐3 fatty acid supplementation compared with placebo for cystic fibrosis</a> </p> <p>The effects of interventions are summarised in the summary of findings table, the quality of the evidence has been graded for pre‐defined outcomes (see above) and definitions of these gradings provided (<a href="./full#CD002201-tbl-0001">summary of findings Table for the main comparison</a>). </p> <section id="CD002201-sec-0064"> <h4 class="title">Primary outcomes</h4> <section id="CD002201-sec-0065"> <h5 class="title">1. Number of respiratory exacerbations</h5> <p>Two studies reported data related to this outcome (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>); three of the studies did not measure respiratory exacerbations (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> <p>One study (n = 13) reported the median (range) number of pulmonary exacerbations, comparing the number of exacerbations in the study to the number in the previous 12 months (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). Investigators only reported the significant change for the within‐group data for the supplement group in the main publication, but further limited data have been obtained from the author to allow a comparison between intervention and placebo (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>) (very low‐quality evidence from this study at this time‐point). </p> <p> <div class="table" id="CD002201-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12 months prior to study begin</b> </p> <p><b>(median (range))</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>During study</b> </p> <p><b>(median (range))</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omega‐3 supplement</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0 (1 ‐ 6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7 (1 ‐ 3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> </tr> </tbody> </table> </div> </p> <p>It is important to note that the number of pulmonary exacerbations did not appear in the original study protocol, and was measured at baseline and 12 months unlike other clinical parameters in the study. Furthermore, the small number of participants in the study increases the possibility that the reduction in pulmonary exacerbations may not have been caused by omega‐3 supplementation. Also, at baseline the median (range) FEV<sub>1</sub> % predicted of participants in the placebo group (n = 7) was lower than in the treatment group (n = 6), 65% (47 to 104) versus 83% (64 to 121), respectively (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> <p>Hanssens also reported on the cumulative number of antibiotic therapy days (IV and oral) for participants compared to the previous 12 months and between groups (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> <p> <div class="table" id="CD002201-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>12 months up to start of study</b> </p> <p><b>median (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Antibiotic days at 9 months</b> </p> <p><b>median (range)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Antibiotic days at 12 months</b> </p> <p><b>median (range)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Omega‐3 supplement</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 days (0 ‐ 122)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.5 days (0 ‐ 43)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.5 days (0 ‐ 56)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Placebo</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60 days (0 ‐ 90)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46 days (15 ‐ 92)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65 days (15 ‐ 113)</p> </td> </tr> </tbody> </table> </div> </p> <p>One further study (n = 45) reported there to be no difference in antibiotic use during the study, compared with a similar time period in the previous year; however, no data on the differences in antibiotic days were reported (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </section> <section id="CD002201-sec-0066"> <h5 class="title">2. Adverse events and dropouts</h5> <p>All five studies reported on adverse events (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>); however, one study simply stated that overall there were no adverse effects of treatment (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> <section id="CD002201-sec-0067"> <h6 class="title">a. Steatorrhoea</h6> <p>One study (n = 12) reported that by six weeks, participants in both treatment and control groups needed to increase their daily dose of pancreatic enzyme capsules due to an increase in steatorrhoea and stool frequency (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). </p> <p>In three studies prior to study start the daily pancreatic enzyme dose was increased for participants in both the intervention and placebo groups to prevent steatorrhoea; there were no reported events of stearrhoea in these three studies (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> <p>One study did not specifically report this adverse event (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> <section id="CD002201-sec-0068"> <h6 class="title">b. Diarrhoea</h6> <p>In the Henderson study, two out of seven participants in the treatment group stopped fish oil supplements because of diarrhoea; the same symptoms caused two out of five participants in the placebo group to withdraw (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). There was no significant difference between the groups, odds ratio (OR) 0.60 (95% confidence interval (CI) 0.05 to 6.80) (<a href="./references#CD002201-fig-0003" title="">Analysis 1.1</a>) (very low‐quality evidence from this study at this time‐point). </p> <p>Diarrhoea was not reported in the remaining studies (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> <section id="CD002201-sec-0069"> <h6 class="title">c. Asthma</h6> <p>Only one cross‐over study (n = 19) reported this event (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Three participants (one in the supplement group and two in the placebo group) had an asthma exacerbation requiring corticosteroid therapy and were excluded from analysis. The authors argued that corticosteroids affect essential fatty acid metabolism (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> </section> <section id="CD002201-sec-0070"> <h6 class="title">d. Stomach pains</h6> <p>Only one study (n = 35) reported that five participants (treatment group not specified) complained of stomach pains; two participants withdrew from the study due to stomach pains (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </section> </section> <section id="CD002201-sec-0071"> <h5 class="title">3. Lung function</h5> <p>Lung function was not measured in one study (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). </p> <section id="CD002201-sec-0072"> <h6 class="title">a. FEV<sub>1</sub> </h6> <p>There were no differences in FEV<sub>1</sub> % predicted reported in the cross‐over Panchaud study (n = 16) at six months (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>), MD 2.00 (95% CI ‐19.11 to 23.11) (<a href="./references#CD002201-fig-0004" title="">Analysis 1.2</a>) (very low‐quality evidence from this study at this time‐point). </p> <p>One short‐term study (n = 16) reported on FEV<sub>1</sub> (L), but investigators reported median (range) values and we are unable to analyse data in this review (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Investigators reported a significant increase from baseline in FEV<sub>1</sub> in the EPA group, median 0.25 L (0.1 L to 0.85 L) compared with the placebo group, median ‐0.1 L (‐1.15 L to 0.24 L) (P = 0.006). Hanssens reported no difference in lung function (FEV<sub>1</sub>% predicted) between groups (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). Keen also reported no difference in lung function (measure not specified) (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </section> <section id="CD002201-sec-0073"> <h6 class="title">b. FVC</h6> <p>There were no differences in FVC % predicted reported in the cross‐over Panchaud study (n = 16) at six months (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>), MD ‐1.00 (95% CI ‐16.65 to 14.65) (<a href="./references#CD002201-fig-0005" title="">Analysis 1.3</a>) (very low‐quality evidence from this study at this time‐point). </p> <p>Lawrence (n = 16) also reported a significant rise in FVC (L) in the EPA group, median 0.6 L (‐0.1 L to 0.75 L) compared with placebo, median 0.0 L (‐0.15 L to 0.35 L) (P = 0.011) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Hanssens reported no difference in lung function (FVC % predicted) between groups (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). Keen reported no difference in lung function (measure not specified) (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </section> </section> </section> <section id="CD002201-sec-0074"> <h4 class="title">Secondary outcomes</h4> <section id="CD002201-sec-0075"> <h5 class="title">1. Quality of life</h5> <p>This outcome was not measured in any of the studies.</p> </section> <section id="CD002201-sec-0076"> <h5 class="title">2. Number of deaths</h5> <p>No deaths occurred in any of the studies (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> </section> <section id="CD002201-sec-0077"> <h5 class="title">3. Clinical variables</h5> <p>The Shwachman score is an overall clinical scoring system in CF, when an increase in the score indicates improvement in clinical conditions (<a href="./references#CD002201-bbs2-0046" title="ShwachmanH , KulczyckiLL . Long term study of 105 patients with cystic fibrosis. American Journal of Diseases of Children1958;96(1):6‐10. ">Shwachman 1958</a>). Lawrence reported a significant increase in Shwachman score in the EPA group, median (range) increase 5% (‐10% to 20%) compared with the placebo group, median (range) increase 0% (‐10% to 0%) (P = 0.034) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> <p>Nutritional parameters were recorded in four studies as exploratory outcomes (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). </p> <p>The cross‐over Panchaud study (n = 15) reported a body mass index (BMI) SD score using the nine centiles for BMI in British girls and boys as normal values and their associated co‐efficient of variation (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). There was no significant difference between the PUFA group and the placebo group after six months, MD 0.00 (95% CI ‐0.64 to 0.64) (<a href="./references#CD002201-fig-0006" title="">Analysis 1.4</a>) (very low‐quality evidence from this study at this time‐point). </p> <p>Two studies reported the median (range) change in weight (kg) which did not allow us to include the data in a meta‐analysis (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Keen (n = 45) reported that at three months the median (range) change in weight in the supplement group was 1.75 kg (0.0 to 3.5; P = 0.001) and in the placebo group 1.0 kg (‐2.0 to 5.5; P = 0.004) (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). Lawrence (n = 19) reported the median (range) change in weight at six months of 1.0 kg (‐1.0 to 3.0) in the supplement group and 0.0 kg (‐1.0 to 3.0) in the placebo group (P = 0.290) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). A further study (n = 15) reported that all participants exhibited low BMI z scores at baseline and these scores remained stable throughout the study (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> <p>One study reported a median (range) reduction in sputum volumes in the treatment group ‐10 mL (‐50 mL to ‐5 mL) compared with placebo 0 mL (0 mL to ‐10 mL) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> </section> <section id="CD002201-sec-0078"> <h5 class="title">4. Bronchial responsiveness</h5> <p>This outcome was not measured in any of the studies.</p> </section> <section id="CD002201-sec-0079"> <h5 class="title">5. Biochemical markers of essential fatty acid status</h5> <p>Panchaud (n = 15) reported a higher EPA content of the neutrophil membrane in the omega‐3 PUFA‐supplemented group compared to the placebo group, MD 0.90 (95% CI 0.46 to 1.34) (<a href="./references#CD002201-fig-0007" title="">Analysis 1.5</a>). However, no difference was observed in DHA membrane concentration between the study groups, MD 0.10 (95% CI ‐0.45 to 0.65) (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>) (<a href="./references#CD002201-fig-0007" title="">Analysis 1.5</a>) (very low‐quality evidence from this study at this time‐point). The leukotriene B<sub>4</sub> to leukotriene B<sub>5</sub> ratio was lower at six months in the omega‐3 PUFA‐supplemented group compared to placebo, MD ‐48.00 (95% CI ‐61.06 to ‐34.94) (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>) (<a href="./references#CD002201-fig-0008" title="">Analysis 1.6</a>). </p> <p>Keen (n = 35) reported means and standard errors (which we converted to SDs to allow analysis in RevMan) on the change from baseline in EPA and DHA content of serum phospholipids and the n6 to n3 ratio (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). There was a significant increase from baseline in both EPA and DHA content of serum phospholipids in the omega‐3 supplemented group compared to placebo, MD 0.70 (95% CI 0.42 to 0.98) and MD 1.10 (95% CI 0.39 to 1.81) respectively (<a href="./references#CD002201-fig-0009" title="">Analysis 1.7</a>). There was also a significant decrease in n‐6/n‐3 ratio in the omega‐3 group compared to placebo, MD ‐1.42 (95% CI ‐2.30 to ‐0.54) (<a href="./references#CD002201-fig-0010" title="">Analysis 1.8</a>). Further biochemical marker data were reported by Keen, but these were reported as medians and ranges which we were not able to analyse in RevMan. Investigators reported the change from baseline in the inflammatory markers, ESR and IL‐8. At three months, ESR decreased significantly in the supplement group from a median (range) of 7 mm/h (3 to 26) at baseline to 6 mm/h (3 to 25) (P = 0.05). Similarly, at the same time‐point, the paper reports a significant decrease of IL‐8 in the supplemented group, but a lack of data for the placebo group allowed no comparison to be made (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> <p>Hanssens reported a greater increase in the essential fatty acid profile in the treatment arm compared to placebo, but no data were available for analysis (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). In the placebo group values remained stable, but after three months supplementation with omega‐3 increased erythrocyte levels of EPA (4.2 fold, P &lt; 0.025) and DHA (1.6 fold, P &lt; 0.05). Further increases of EPA (4.2 fold, P &lt; 0.02) and DHA (1.9 fold, P &lt; 0.05) were seen at six months, but no further increases were seen at 12 months (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). Levels of AA decreased at three months (1.2 fold, P &lt; 0.05) and six months (1.3 fold, P &lt; 0.01) with a further decrease (3.5 fold, P &lt; 0.01) seen at 12 months (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002201-sec-0080" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002201-sec-0080"></div> <p>The most notable feature highlighted by this review was the lack of data for many of the outcomes likely to be meaningful to people with or making treatment decisions about CF. Information was limited on a number of the primary outcomes that we would have expected to find in a RCT. Across all outcomes the quality of the evidence was judged to be very low, meaning we are very uncertain whether the effects seen were due to supplementation or not. </p> <section id="CD002201-sec-0081"> <h3 class="title" id="CD002201-sec-0081">Summary of main results</h3> <p>Five studies with a total of 106 participants were included in the review, but these were heterogeneous in design and duration. Three had a parallel design (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>) and two were of cross‐over design (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). They all administered a form of omega‐3 supplementation; two studies compared this to olive oil and three to placebo. The duration of the studies lasted from six weeks to 12 months. Data were not consistently reported in a form we were able to analyse and the results we were able to present did not show consistent effects across studies. </p> <p>Two studies reported on the number of pulmonary exacerbations, the review's first primary outcome, but we could not analyse the results in this review (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). At three months one study reported no difference in antibiotic use during the study period compared with a similar time period in the previous year (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). The second study reported a reduction in the median (range) number of respiratory exacerbations in the treatment group compared to the 12 months prior to study begin, but did not report data for the control group (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). The same study reported a greater decrease in the mean (range) cumulative number of days of antibiotic therapy (IV and oral) in the treatment group compared to the control group at both nine and 12 months (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> <p>Few adverse events were seen with omega‐3 supplementation (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). Increased steatorrhoea was reported by one study which led to participants needing to increase their daily dose of pancreatic enzymes (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>); but it should be noted that three further studies increased pancreatic enzyme dose prior to study begin in order to avoid steatorrhoea (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). One study reported no difference between groups in incidences of diarrhoea (<a href="./references#CD002201-bbs2-0002" title="HendersonWR . Omega‐3 supplementation in cystic fibrosis. Pediatric Pulmonology1992;14(S8):S21.2. [CFGD Register: GN45a] HendersonWRJr , AstleySJ , McCreadyMM , KushmerickP , BeckerJU , RamseyB . Absorption of omega (w) ‐3 fatty acids in CF patients. Pediatric Pulmonology1992;14(S8):311. [CFGD Register: GN45b] HendersonWRJr , AstleySJ , McCreadyMT , KushmerickP , CaseyS , BeckerJW , et al. Oral absorption of omega‐3 fatty acids in patients with cystic fibrosis who have pancreatic sufficiency and in healthy control subjects. Journal of Pediatrics1994;124(3):400‐8. [CFGD Register: GN45c] ">Henderson 1994</a>). Three asthma exacerbations were reported by one study (one in the supplement group and two from the control group) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). Stomach pains in five participants were reported in one thee‐month study, but it was not specified in which group these occurred (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> <p>Four studies reported on lung function (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>), but only one cross‐over study reported data we were able to analyse (<a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). One study reported a significant increase in FEV<sub>1</sub> (L) in the supplement group compared to placebo at six weeks (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>), but two studies showed no difference between treatment and control groups in FEV<sub>1</sub> % predicted at six months (<a href="./references#CD002201-fig-0004" title="">Analysis 1.2</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>) or at one year (narrative only, no data presented) (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). The six‐week study also reported an increase in FVC (L) in the supplement group compared with placebo (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>), but again this was not reflected in results for FVC % predicted at six months (<a href="./references#CD002201-fig-0005" title="">Analysis 1.3</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>) or at one year (no data presented) (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). A fourth study also reported no change in lung function (at three months), but the unit of measurement was not specified (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> <p>With regards to the review's secondary outcomes, no deaths were reported in any of the five studies and quality of life and bronchial responsiveness were not reported by any study. </p> <p>Each study reported different clinical variables. One study reported improved median Schwachman scores and reduced sputum volumes with supplementation compared to placebo at three months (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). This study also reported no difference between groups in the median change in weight (kg) at six weeks (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>); however, a further study reported a greater median increase in weight (kg) in the supplement group at three months (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). At six months, the cross‐over study showed no difference between groups in BMI SD score (<a href="./references#CD002201-fig-0006" title="">Analysis 1.4</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>); this was also true for BMI z score as reported narratively at 12 months (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> <p>Three studies reported on biochemical markers of essential fatty acid status (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>; <a href="./references#CD002201-bbs2-0005" title="PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , BoulatO , et al. Biological effects of a dietary omega‐3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: A randomised, crossover placebo‐controlled trial. Clinical Nutrition2006;25(3):418‐27. [CFGD Register: GN109b] PanchaudA , SautyA , KernanY , DecosterdLA , BuclinT , RouleM . Dietary Supplementation with omega 3 in cystic fibrosis (CF) patients. Journal of Cystic Fibrosis2005;4 Supplement 1:S88. [CFGD Register: GN109a] ">Panchaud 2006</a>). At three months in the omega‐3 group compared to placebo, Keen showed an increase from baseline in both EPA and DHA content of serum phospholipids (<a href="./references#CD002201-fig-0009" title="">Analysis 1.7</a>) and also a significant decrease in n‐6/n‐3 ratio (<a href="./references#CD002201-fig-0010" title="">Analysis 1.8</a>). Data from this study also showed significant median decreases in ESR and IL‐8 in the supplement group at three months, but there were no data for the placebo group (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). At six months the cross‐over Panchaud study showed a higher EPA content of the neutrophil membrane in the supplement group compared to the placebo group, but no difference in DHA membrane concentration (<a href="./references#CD002201-fig-0007" title="">Analysis 1.5</a>); furthermore, the leukotriene B<sub>4</sub> to leukotriene B<sub>5</sub> ratio was lower at six months in the omega‐3 group compared to placebo (<a href="./references#CD002201-fig-0008" title="">Analysis 1.6</a>). The one‐year study reported a greater increase in the essential fatty acid profile and a decrease in AA levels in the treatment arm compared to placebo; however, P values were only presented for within‐group data for the supplement group and no data for the placebo group (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> </section> <section id="CD002201-sec-0082"> <h3 class="title" id="CD002201-sec-0082">Overall completeness and applicability of evidence</h3> <p>The included trials recruited children and adults with CF, although sample sizes were small. The participants were mixed in terms of both gender and age. It is important to note that the effect of omega‐3 supplementation on children under five years of age was not studied in these studies. </p> <p>The dose of both EPA and DHA varied considerably across the studies with DHA doses ranging from 100 mg to 2.21 g and EPA doses ranging from 150 mg to 2.7 g. One study calculated the dose of omega‐3 supplementation based on the participant's weight. The differences in dose of omega‐3 and differences in the placebo used, mean that we are unable to use these RCTs to make a generalisable finding for people with CF. </p> </section> <section id="CD002201-sec-0083"> <h3 class="title" id="CD002201-sec-0083">Quality of the evidence</h3> <p>The evidence from the studies included in this review was difficult to appraise due to very low participant numbers, low event rates and limited reporting. We judged the quality of the evidence from the studies for all five outcomes to be very low (<a href="./full#CD002201-tbl-0001">summary of findings Table for the main comparison</a>). There was inconsistency in the weight indices measured and time‐points across the studies. Meaurements of EPA and DHA varied varied considerably across studies. Findings for pulmonary exacerbations were presented as median data without full ranges compared to placebo. Other references to pulmonary exacerbation rates were noted, but failed to provide data on the changes. Analysis of data related to FEV<sub>1</sub> % predicted and FVC % predicted was limited with small sample sizes and limited reporting of data. The risk of bias was unclear across several domains including randomisation, allocation concealment, incomplete outcome assessment and selective reporting </p> </section> <section id="CD002201-sec-0084"> <h3 class="title" id="CD002201-sec-0084">Potential biases in the review process</h3> <p>We conducted a comprehensive literature search of online journal databases using the Cystic Fibrosis and Genetic Disorders Review Group’s Cystic Fibrosis Trials Register and also of journal conference abstracts with no restriction on publication status or language of potentially eligible studies. Although an exhaustive and comprehensive search was conducted, there is an inherent risk that studies may have been missed. Two authors independently applied the inclusion and exclusion criteria to the identified studies and excluded studies that were not relevant. Included studies were appraised for bias and data was extracted using a pre‐determined form according to the previously published review. Where disagreements existed, these were solved through mutual agreement from the authors after discussion Neither of the authors have received direct or indirect payments from the companies responsible for the development of any agents included in this review. This review has assessed all available published study data. Study authors were contacted for relevant unpublished information and individual participant data. Where unpublished data have been used, this has been noted in the review. </p> </section> <section id="CD002201-sec-0085"> <h3 class="title" id="CD002201-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>At present, we are unaware of any recently published data available about the effects of long‐term supplementation or appropriate dosage of omega‐3 fatty acids. Current nutritional management guidelines for CF do not recommend routine supplementation with omega‐3 fatty acids (<a href="./references#CD002201-bbs2-0027" title="UK CFTrust . CF Trust Consensus Documents: Nutritional Management of Cystic Fibrosis. September 2016. www.cysticfibrosis.org.uk/˜/media/documents/the‐work‐we‐do/care/consensus‐documents‐with‐old‐address/nutritional‐management‐of‐cystic‐fibrosis‐sep‐16.ashx?la=en (accessed 10 January 2020). ">CF Trust 2016</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002201-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow (PRISMA) diagram" data-id="CD002201-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow (PRISMA) diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002201-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 1 Adverse events." data-id="CD002201-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 1 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 2 FEV1 % predicted (post‐treatment)." data-id="CD002201-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 2 FEV<sub>1</sub> % predicted (post‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 3 FVC % predicted (post treatment)." data-id="CD002201-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 3 FVC % predicted (post treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 4 BMI (SD score) (post treatment)." data-id="CD002201-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 4 BMI (SD score) (post treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 5 EPA and DHA % content of neutrophil membrane (post treatment)." data-id="CD002201-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 5 EPA and DHA % content of neutrophil membrane (post treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 6 Leukotriene B4 to leukotriene B5 ratio (post treatment)." data-id="CD002201-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 6 Leukotriene B4 to leukotriene B5 ratio (post treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 7 EPA and DHA content of serum phospholipids (change from baseline)." data-id="CD002201-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 7 EPA and DHA content of serum phospholipids (change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002201-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/urn:x-wiley:14651858:media:CD002201:CD002201-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_t/tCD002201-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 8 N6/N3 ratio content of serum phospholipids (change from baseline)." data-id="CD002201-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Omega‐3 fatty acids versus placebo, Outcome 8 N6/N3 ratio content of serum phospholipids (change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/media/CDSR/CD002201/image_n/nCD002201-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002201-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: omega‐3 fatty acid supplementation compared with placebo for cystic fibrosis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Omega‐3 fatty acid supplementation compared with placebo for cystic fibrosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b>: children and adults with cystic fibrosis </p> <p><b>Settings</b>: outpatients </p> <p><b>Intervention</b>: oral omega‐3 supplementation (EPA or DHA, or both) </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Omega‐3 supplementation</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of pulmonary exacerbations</b> (median number of exacerbations during the study) </p> <p>Follow‐up: 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The number of exacerbations in the placebo group was greater than in the omega‐3 group (3.5 versus 1.7 (range 1 ‐ 3)). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>a,b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors only report the number of exacerbations in the supplemented group compared to the 12 months prior to the trial. Extra data was provided by the study authors to allow a between group comparison. </p> <p>This outcome was not included in the study protocol.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b>: diarrhoea </p> <p>Follow‐up: 6 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported drop out due to diarrhoea. 2 out of 7 participants in the fish oil group dropped out and 2 out of 5 participants in the placebo group, OR 0.6 (0.05 to 6.79). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.6 (0.05 to 6.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other adverse events included stomach pains (5/35 participants) but the intervention arm wasn't specified (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FEV<sub>1</sub> % predicted</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted was 64% in the control group. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FEV<sub>1</sub> % predicted in the intervention group was 2% higher (19.1% lower to 23.11% higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 2.00 (19.11 to 23.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further study (n = 16) reported a significant increase from baseline in the EPA group compared to the control group measured in L compared to the placebo group (P = 0.06) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> <p>Two studies reported no difference in FEV<sub>1</sub> % predicted or lung function (measurement not stated) between groups (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>FVC % predicted</b> </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FVC % predicted in the control group was 81%.</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean FVC % predicted in the intervention group was 1% lower (16.65 % lower to 14.65 % higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD ‐1.00 (‐16.65 to 14.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study reported a significant rise in FVC (L) in the EPA group (P = 0.01) (<a href="./references#CD002201-bbs2-0004" title="LawrenceR , SorrellT . Eicosapentaenoic acid in cystic fibrosis: evidence of a pathogenetic role for leukotriene B4. Lancet1993;342(8869):465‐9. [CFGD Register: GN44a] LawrenceR , SorrellT . Modulation of abnormal neutrophil response to leukotriene B4 in the chronic pseudomonal lung infection of cystic fibrosis. Australian and New Zealand Journal of Medicine1993;23:442. [CFGD Register: GN44b] ">Lawrence 1993</a>). </p> <p>2 studies reported no difference in FVC between groups, but no data were available for analysis (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>; <a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Growth and nutrition</b>: BMI SD score </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No significant difference was seen between the PUFA group and the placebo group after 6 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MD 0.00 (95 % CI ‐0.64 to 0.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A further study reported on BMI but reported only that BMI z scores remained stable throughout the study (<a href="./references#CD002201-bbs2-0001" title="HanssensL , ThiebaultI , LefevreN , MalfrootA , GasparV , KnoopC , et al. Benefits of long‐term supplementation with omega‐3 polyunsaturated fatty acids in cystic fibrosis. Journal of Cystic Fibrosis: Official Journal of the European Cystic Fibrosis Society. 2015; Vol. 14 Suppl 1:S52. [Abstract no.: ePS05.9; CENTRAL: 1081482; CFGD Register: GN247a; CRS: 5500135000001304] HanssensL , ThiebautI , LefevreN , MalfrootA , KnoopC , DuchateauJ , et al. The clinical benefits of long‐term supplementation with omega‐3 fatty acids in cystic fibrosis patients ‐ a pilot study. Prostaglandins, Leukotrienes, and Essential Fatty Acids2016;108:45‐50. [CFGD Register: GN247b; DOI: 10.1016/j.plefa.2016.03.014] ">Hanssens 2016</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Biochemical markers of essential fatty acid status</b>: EPA and DHA % content of neutrophil membrane </p> <p>Follow‐up: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 study reported a higher EPA content of the neutrophil membrane in the omega‐3 PUFA‐supplemented group compared to the placebo group, MD 0.90 (95% CI 0.46 to 1.34). </p> <p>In the same study, no difference was observed in DHA membrane concentration between groups, MD 0.10 (95% CI ‐0.45 to 0.65) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 6 months, Keen reported a significant increase from baseline in both EPA and DHA content of serum phospholipids in the omega‐3 supplemented group compared to placebo, MD 0.70 (95% CI 0.42 to 0.98) and MD 1.10 (95% CI 0.39 to 1.81), respectively (<a href="./references#CD002201-bbs2-0003" title="KeenC , OlinA , ErikssonS , EkmanA , LindbladA , BasuS , et al. Supplementation with fatty acids influences the airway nitric oxide and inflammatory markers in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition2010;50(5):537‐44. [CFGD Register: GN129b] KeenC , OlinA , ErikssonS , LindbladA , EkmanA , BasuS , et al. Supplementation with polyunsaturated fatty acids influences the inflammatory response and airway nitric oxide in patients with cystic fibrosis. European Respiratory Society Annual Congress. 2008:541s. [CFGD Register: GN129a] ">Keen 2010</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>DHA</b> : docosahexaenoic acid; <b>EPA</b> : eicosapentaenoic acid; <b>FEV<sub>1</sub> </b> : forced expiratory volume in 1 second; <b>FVC</b> : forced vital capacity; <b>MD</b> : mean difference; <b>OR</b> : odds ratio; <b>PUFA</b> : polyunsaturated fatty acid; <b>SD</b>: standard deviation. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to risk of bias within the included study for this outcome. There was uncertainty around allocation concealment and blinding and a high risk of bias due to selective reporting. </p> <p><sup>b</sup>Downgraded once due to imprecision from very low participant numbers and low event rates. </p> <p><sup>c</sup>Downgraded once due to risk of bias within the included study. It was unclear whether allocation was concealed and whether the outcomes were predefined as there was no protocol available. </p> <p><sup>d</sup>Downgraded twice due to very low participant numbers (n = 12) and low event rates. </p> <p><sup>e</sup>Downgraded twice due to risk of bias within the trial. The risk of bias was unclear across several domains including; randomisation, allocation concealment, incomplete outcome assessment and selective reporting. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: omega‐3 fatty acid supplementation compared with placebo for cystic fibrosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/full#CD002201-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002201-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omega‐3 fatty acids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Diarrhoea and eructation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 FEV<sub>1</sub> % predicted (post‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 FVC % predicted (post treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 BMI (SD score) (post treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 EPA and DHA % content of neutrophil membrane (post treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 EPA at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 DHA at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Leukotriene B4 to leukotriene B5 ratio (post treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 EPA and DHA content of serum phospholipids (change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 EPA At 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 DHA at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 N6/N3 ratio content of serum phospholipids (change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 At 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Omega‐3 fatty acids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002201.pub6/references#CD002201-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002201.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002201-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002201-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002201-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD002201-note-0002">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD002201-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002201-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD002201-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002201\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002201\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002201\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002201\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002201\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XHP2gG4h&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002201.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002201.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002201.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002201.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002201.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719118381"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002201.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719118384"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002201.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de0f3cdc81be4',t:'MTc0MDcxOTExOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 